SCNX

0.3315

2.18% -0.0074

Vorhandelsmarkt: .34 0.0085 +2.56%

Scienture Holdings Inc (SCNX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.3389

Offen:

$0.3315

24-Stunden-Volumen:

140.63K

Relative Volume:

0.06

Marktkapitalisierung:

$13.61M

Einnahmen:

$656.60K

Nettoeinkommen (Verlust:

$-16.79M

KGV:

-0.3086

EPS:

-1.0743

Netto-Cashflow:

$-11.12M

1W Leistung:

-8.85%

1M Leistung:

-27.78%

6M Leistung:

-29.08%

1J Leistung:

-66.27%

1-Tages-Spanne:

$0.3315

$0.3441

1-Wochen-Bereich:

$0.3315

$0.385

52-Wochen-Spanne:

$0.2382

$2.60

Scienture Holdings Inc Stock (SCNX) Company Profile

Firmenname

Scienture Holdings Inc

Sektor

Healthcare (1066)

Branche

Pharmaceutical Retailers (7)

Telefon

(800) 261 0281

Adresse

20 AUSTIN BLVD., COMMACK

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

SCNX's Discussions on Twitter

Compare SCNX vs HITI, PETS, POM, MEDS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SCNX Scienture Holdings Inc	0.3315	14.29M	656.60K	-16.79M	-11.12M	-1.0743
HITI High Tide Inc	2.54	222.31M	486.49M	-33.29M	10.86M	-0.3627
PETS Petmed Express Inc	1.62	35.77M	179.02M	-57.29M	-33.01M	-2.7487
POM Pomdoctor Ltd Adr	0.7547	6.77M	0	0	0	0.00
MEDS Trxade Health Inc	1.62	2.76M	7.15M	4.03M	-11.33M	-5.40

Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten

Sep 09, 2026

Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill

Sep 09, 2026

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - marketscreener.com

Sep 09, 2026

Sep 03, 2026

Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView

Sep 03, 2026

Aug 31, 2026

Scienture (SCNX) CFO shows no personal stake in company stock - stocktitan.net

Aug 31, 2026

Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget

Aug 31, 2026

Aug 23, 2026

SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative

Aug 23, 2026

Aug 21, 2026

Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn

Aug 21, 2026

Aug 20, 2026

Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn

Aug 20, 2026

Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart

Aug 20, 2026

Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative

Aug 20, 2026

Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade

Aug 20, 2026

Aug 19, 2026

Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn

Aug 19, 2026

Aug 18, 2026

$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo

Aug 18, 2026

Aug 17, 2026

SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn

Aug 17, 2026

SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn

Aug 17, 2026

Aug 14, 2026

Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com

Aug 14, 2026

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative

Aug 14, 2026

Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan

Aug 13, 2026

Aug 12, 2026

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance

Aug 12, 2026

Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria

Aug 12, 2026

Scienture launches naloxone nasal spray for opioid overdose - Investing.com

Aug 12, 2026

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com

Aug 12, 2026

Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com

Aug 12, 2026

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance

Aug 12, 2026

Aug 07, 2026

Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

Aug 07, 2026